XML 36 R23.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Long-Lived Assets by Geography The CODM function is regularly provided with the following significant segment expenses:
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Oncology clinical trial related costs$75,236 $22,980 $179,423 $64,832 
Acquired in-process research and development— — — 15,007 
Compensation related costs, excluding stock-based compensation21,469 12,840 54,123 32,751 
Stock-based compensation130,761 19,371 620,641 39,966 
Other expenses (1)
6,745 3,187 15,312 7,828 
Total segment expenses234,211 58,378 869,499 160,384 
Other income, net2,418 4,578 9,085 8,949 
Interest expense— (2,454)— (8,677)
Net loss$(231,793)$(56,254)$(860,414)$(160,112)
(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.